Pursuant to the provisions of Regulation 30 (read with Part A of Schedule IIf) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations"), and in ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Integrated Proteins Limited's Board of Directors met on 12 February 2026 and approved the unaudited financial results for the quarter and nine months ended 31 December 2025, along with the limited review report by statutory auditors B.B. Gusani & Associates. The company also reviewed its overall business. The auditor issued a clean (unmodified) limited review opinion with no qualifications or emphasis-of-matter paragraphs. The company also confirmed there has been no deviation or variation in the utilisation of Rs. 1,744.88 lakhs raised through preferential issues in January–February 2025, which was earmarked for capital expenditure (Rs. 1,054.75 lakhs) and general corporate purposes (Rs. 690.13 lakhs). The company has only one reportable segment, so segment-wise disclosure is not required.
Routine quarterly results submission with a clean auditor review is neutral for the stock. Investors may want to compare the detailed Q3 and 9M FY26 revenue and profit figures against prior periods once the clearer version is available, as the small-cap financials and tight margins make earnings quality an important watchpoint.